Forty-seven clinically relevant late-phase programs identify development trajectories for PD-1 and PD-L1 therapies through 2030
47 late-phase programs aim to improve PD-1/PD-L1 cancer therapies
This narrative review analyzes registry-derived clinical trial data to identify future directions for PD-1 and PD-L1 inhibitor therapies. Th…
A new review maps 47 late-phase programs working to overcome limits of PD-1/PD-L1 cancer treatments through 2030.
Next-generation engineered constructs aim to overcome immunosuppressive tumor microenvironments in refractory malignancies
New framework aims to improve treatment for solid tumors
This systematic review synthesizes clinical data regarding CAR-T cells and bispecific antibodies for solid tumors and refractory malignancie…
Doctors are looking at new ways to use CAR-T cells and bispecific antibodies earlier in the treatment of hard-to-treat cancers.
Systematic review of advancements and challenges in NK cell immunotherapy for malignancies
New NK cell therapies show promise for treating cancer
This systematic review evaluates Natural Killer (NK) cell immunotherapy, including CAR-NK, BiKEs, TriKEs, and CIML-NK cells, for hematologic…
New ways to use Natural Killer cells could help fight cancer while keeping the risk of dangerous immune reactions very low.
Narrative review discusses NTS1-targeted molecular probes for malignancies with noted translation challenges
New Cancer Scan Targets Tumors Hidden from View
This narrative review examines the potential of NTS1-targeted molecular probes for treating malignancies.
Researchers are building a smarter tool to find and treat cancer cells more accurately.
Review explores JAK inhibitor combination with PD-1 blockade for overcoming immunotherapy resistance
Review explores combining JAK inhibitors with immunotherapy for resistant cancers
A systematic review discusses the rationale for combining JAK inhibitors with PD-1 blockade immunotherapy based on emerging preclinical and …
Blocking inflammation around tumors with JAK inhibitors may help immune drugs work better for cancers that have stopped responding to standa…
Larger baseline tumor burden linked to shorter OS in rare cancers treated with nivolumab plus ipilimumab
Does tumor size predict how well immunotherapy works for rare cancers?
A secondary analysis of a phase 2 basket trial in 722 patients with rare/ultrarare malignancies found that larger baseline tumor burden was …
For rare cancers treated with immunotherapy, larger tumors at the start were linked to shorter overall survival, but not to how long patient…
Questions about Malignancies
Does having a larger baseline tumor burden affect survival in rare cancers treated with nivolumab?
In rare cancers treated with nivolumab plus ipilimumab, having a larger tumor burden at the start of treatment is linked to shorter overall survival.
Full answer →